/
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.
The business is unprofitable at the operating level (-1031.46% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$82M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$10M
Net Income (TTM)
-$90M
▼ -13.4% YoY
Op. Margin
-985.93%
ROIC
-25.73%
▲ +11.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$89M
▼ -58.7% YoY
Op. Cash Flow (TTM)
-$88M
▼ -58.4% YoY
Net Debt
-$379M
Net Cash Position
Cash & Equiv.
$383M
Continue Research